20Med Therapeutics

What 20Med Therapeutics does

20Med Therapeutics B.V. is a Dutch privately-held biotechnology company spun out of the University of Twente that develops a proprietary bio-responsive polymeric nanoparticle (PNP) platform as an alternative to lipid nanoparticles (LNPs) for intracellular delivery of nucleotide-based payloads, including mRNA, DNA and oligonucleotides. The platform is built on poly(amido)amine (PAA) polymers engineered for endosomal escape via the proton sponge effect and glutathione-triggered cytosolic payload release, and is supported by worldwide composition-of-matter patents independent of the LNP IP landscape.

The company's lead application is mRNA vaccines for seasonal influenza, with the CEPI-funded program aiming to enable 2–8°C storage and remove the need for frozen cold-chain logistics. Beyond influenza, 20Med is applying the PNP platform to DNA vaccines (in collaboration with Touchlight, leveraging Gates Foundation funding), immuno-oncology and therapeutic cancer vaccines (via the Oncode-PACT consortium, backed by a EUR 325 million National Growth Fund investment), and animal-health vaccines with multiple veterinary partners. The science is validated through peer-reviewed publications including a 2024 Molecular Therapy: Nucleic Acids paper demonstrating protective efficacy of an mRNA influenza vaccine in a ferret challenge model.

20Med operates as a B2B platform licensor and co-developer rather than a product vendor. Revenue mechanics are limited to research collaborations, development partnerships, and licensing arrangements (the CEPI USD 850k grant is the most concrete disclosed funding line); no commercial pricing or end-product sales exist. The company is led by CEO Michiel Lodder, PhD (ex-Lanthio/Pepscan/OctoPlus), CBO Hugo Fry (ex-Sanofi UK, Sanofi Pasteur, RQ Bio), and CSO Jaap Rip, PhD (ex-Nanomi), supported by a Supervisory Board chaired by Michel Baijot. The company is headquartered in Leiden with R&D operations in Leiden Bioscience Park and Enschede, employs 1–10 people, and is currently preclinical.

Name

20Med Therapeutics

Legal name

20Med Therapeutics B.V.

Website

https://20medtx.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

20Med Therapeutics is a Dutch preclinical biotechnology company that develops proprietary bio-responsive polymeric nanoparticles (PNPs) as an alternative to lipid nanoparticles for intracellular delivery of mRNA and DNA vaccines, serving pharmaceutical and research partners in infectious disease, immuno-oncology, and animal health.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Delivery Technology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

akta.pro secondary industry

Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

Keywords

• Polymeric nanoparticles
• RNA drug delivery
• MRNA vaccine delivery
• Non-viral delivery
• Bioresponsive polymers

Headquarters

HQ city

Enschede

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Technology partnerships and licensing: 20Med partners with pharmaceutical companies, research institutions, and organizations to develop RNA and DNA vaccines and therapeutics using their proprietary PNP platform. Revenue is generated through research collaborations, development partnerships, and technology licensing arrangements with partners including CEPI, Touchlight, and others.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

20Med Therapeutics develops a proprietary bio-responsive polymeric nanoparticle (PNP) platform composed of poly(amido)amines (PAA) for the intracellular delivery of mRNA, DNA, and oligonucleotide payloads. The platform supports development of vaccines and therapeutics across infectious disease (mRNA influenza), therapeutic cancer vaccines (immuno-oncology), DNA vaccines, and animal health. The technology is offered to pharmaceutical and biotech partners through research collaborations, co-development agreements, and licensing arrangements.

Product overview

20Med Therapeutics offers a proprietary polymeric nanoparticle (PNP) platform technology as a non-viral delivery solution for RNA and DNA-based vaccines and therapeutics. The platform consists of bio-responsive poly(amido)amine nanoparticles that protect fragile nucleotide payloads and enable controlled intracellular release. Applications span infectious disease vaccines (mRNA and DNA), therapeutic cancer vaccines (immuno-oncology), and animal health. The lead program focuses on mRNA influenza vaccines with a partnership with CEPI for thermostable vaccine development. The platform is positioned as an alternative to lipid nanoparticle (LNP) delivery technology.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Preclinical data demonstrated protective effect in ferret influenza challenge model with no local or systemic reactogenicity, strong humoral and cellular immune responses, and reduced clinical symptoms following virus exposure
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and minor.

• TouchlightcoreStrategic or Co-development Partner · 18 April 2023April 2023 collaboration to establish a novel vaccination platform combining Touchlight's rapid enzymatic doggybone DNA with 20Med's bio-responsive nanoparticle technology. Part of Touchlight's funding from the Bill & Melinda Gates Foundation to evaluate the potential applicability of this technology combination for DNA vaccine delivery.
• CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development Partner · 2 February 2023February 2023 partnership to advance 20Med's bio-responsive polymeric nanoparticle technology to eliminate the need for frozen storage of mRNA vaccines. CEPI provided up to USD 850,000 for proof-of-concept development and preclinical studies to assess whether the technology can deliver mRNA vaccines as effectively as lipid nanoparticles. Focus on developing thermostable vaccines for influenza to improve equitable global access to mRNA-based vaccines.
• Oncode-PACTcoreStrategic or Co-development Partner · 15 April 202220Med participates in the Oncode-PACT cancer research consortium, advancing polymeric nanoparticle technology for therapeutic cancer vaccines. The National Growth Fund invests 325 million EUR in Oncode-PACT to accelerate preclinical development. Therapeutic cancer vaccines aim to stimulate the patient's immune system against specific tumor antigens.
• Wageningen UniversityminorStrategic or Co-development Partner · 1 June 2021Collaboration with Wageningen University department of Virology to test efficacy of multiple polymer nanoparticle mRNA vaccine candidates in preclinical models. Part of SARS-CoV-2 variant research project.
• University of TwenteminorStrategic or Co-development Partner · 1 June 2021Collaboration with University of Twente department of Biomaterial Science and Technology. 20Med was spun out of the University of Twente and combines leading material science expertise with biopharmaceutical know-how. Testing efficacy of multiple polymer nanoparticle mRNA vaccine candidates in preclinical models for SARS-CoV-2 variants.

Scale indicators2 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• BioNTech: BioNTech is a leading mRNA therapeutics company partnered with Pfizer on Comirnaty and uses LNP delivery. Comparable as an incumbent nucleic-acid-vaccine developer against whose delivery standard 20Med benchmarks its PNP platform.
• Translate Bio (Sanofi): Translate Bio (acquired by Sanofi in 2021) developed mRNA therapeutics with proprietary lipid nanoparticle delivery technology. Comparable to 20Med as a platform-play in mRNA delivery that ultimately partnered with a large pharma, illustrating the strategic pathway 20Med is pursuing.
• Moderna: Moderna is the dominant mRNA vaccine and therapeutics company with validated LNP delivery platform and approved products (Spikevax). Indirect comparable as the primary incumbent 20Med's PNP platform seeks to differentiate against, particularly for thermostable and equitable-access vaccines.
• Arcturus Therapeutics: Arcturus is a clinical-stage mRNA medicines company developing vaccines and therapeutics using its own delivery platform (LUNAR). Comparable to 20Med as a delivery-platform-owning mRNA developer though it uses lipid-based rather than polymeric nanoparticles.
• CureVac: CureVac is an mRNA technology company developing vaccines and therapeutics, with proprietary delivery formulations. Comparable to 20Med as an mRNA-platform developer with its own delivery IP, though operating at later clinical stage.

Direct peers

• Precision NanoSystems (Cytiva): Precision NanoSystems (now part of Cytiva) provides nanoparticle formulation technologies and instruments for development of RNA therapeutics and vaccines. Comparable to 20Med as a delivery technology enabler for nucleic acid payloads.
• Genevant Sciences: Genevant develops lipid nanoparticle delivery systems for RNA therapeutics and vaccines, licensing its LNP platform to multiple pharma partners. Directly comparable to 20Med as a delivery-platform-focused company enabling nucleic acid therapeutics.
• Acuitas Therapeutics: Acuitas develops lipid nanoparticle (LNP) delivery technology for mRNA therapeutics and is the supplier of LNPs for several major mRNA vaccine programs including Pfizer/BioNTech's. Direct comparable to 20Med as a non-viral nucleic acid delivery platform company serving pharma partners.

Emerging players

• Esperovax: Esperovax develops polymeric and non-LNP delivery systems for nucleic acid vaccines and therapeutics, focused on thermostable formulations. Closest direct emerging competitor to 20Med in polymeric nanoparticle-based RNA/DNA delivery.
• Touchlight Genetics: Touchlight develops enzymatic doggybone DNA (dbDNA) technology for vaccines and gene therapy, and is a current 20Med partner combining dbDNA with PNPs. Comparable as an emerging nucleic-acid platform company in the DNA vaccine space with overlapping commercial relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/20MedThera
• LinkedInlinkedin.com/company/20med-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 20Med Therapeutics